Putnam Investments’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Putnam Investments’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-28,830	Closed	-$1.04M	–	1353
2017 Q1	$1.04M	Sell	28,830 -3,545	-11%	-$156K	﹤0.01%	990
2016 Q4	$1.62M	Sell	32,375 -265	-0.8%	-$13.9K	﹤0.01%	895
2016 Q3	$1.71M	Sell	32,640 -22,504	-41%	-$1.07M	﹤0.01%	889
2016 Q2	$2.28M	Sell	55,144 -356,554	-87%	-$15.5M	0.01%	887
2016 Q1	$16.7M	Sell	411,698 -85,892	-17%	-$2.95M	0.04%	331
2015 Q4	$20.6M	Buy	497,590 +6,095	+1%	+$204K	0.05%	305
2015 Q3	$7.56M	Buy	491,495 +45,195	+10%	+$971K	0.02%	520
2015 Q2	$11.1M	Buy	446,300 +2,000	+0.5%	+$44.6K	0.02%	446
2015 Q1	$10.2M	Hold	444,300	–	–	0.02%	496
2014 Q4	$12M	Hold	444,300	–	–	0.02%	456
2014 Q3	$5.21M	Hold	444,300	–	–	0.01%	755
2014 Q2	$6.91M	Sell	444,300 -3,272	-0.7%	-$46.9K	0.01%	635
2014 Q1	$8.8M	Buy	447,572 +197,572	+79%	+$3.35M	0.02%	516
2013 Q4	$4.2M	Buy	+250,000	New	+$3.11M	0.01%	819

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Putnam Investments's FPRX Position: Q2 2017 in Review

Putnam Investments sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 28,830 shares — an estimated $1.04M sold.

Putnam Investments first reported a position in FPRX in Q4 2013 and held it in 14 quarters. The position peaked at $20.6M in Q4 2015. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

Putnam Investments reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Putnam Investments sold 28,830 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $1.04M.
Putnam Investments first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 14 quarters.
Putnam Investments's Five Prime Therapeutics, Inc. position peaked at $20.6M in Q4 2015.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Putnam Investments's 13F filing for Q2 2017, filed 14 Aug 2017.